Suppr超能文献

尿素和肌酐动力学预测持续非卧床腹膜透析的临床结局

Clinical outcome of continuous ambulatory peritoneal dialysis predicted by urea and creatinine kinetics.

作者信息

Brandes J C, Piering W F, Beres J A, Blumenthal S S, Fritsche C

机构信息

Department of Medicine, Medical College of Wisconsin, Milwaukee.

出版信息

J Am Soc Nephrol. 1992 Mar;2(9):1430-5. doi: 10.1681/ASN.V291430.

Abstract

The effectiveness of urea kinetics (Kt/V, where K is urea clearance, t is treatment time, and V is the volume of distribution for urea) to assess the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and clinical outcome has not been established prospectively, and cross-sectional clinical studies have been inconclusive. A minimum weekly creatinine clearance of 40 to 50 L is recommended, but the adequacy of this dose is unproven. We introduced a simpler approach to creatinine kinetics in the form of an efficacy number (EN) calculated from data obtained in a standardized 4-h dwell exchange. To determine the most effective model for predicting CAPD adequacy, residual renal function, weekly Kt/V urea, weekly creatinine clearance standardized to body surface area, and EN (liters per gram of creatinine per day) were measured in 18 stable CAPD patients followed prospectively for at least 12 months. Patients were divided into three groups, good (G), intermediate (I), and poor (P), on the basis of uremic symptoms, mortality, hospital days, biochemical indices, and the need for transfer to hemodialysis. When comparing groups G (N = 6) and P (N = 8), weekly Kt/V were 2.3 +/- 0.2 versus 1.5 +/- 0.1 (P less than 0.005), weekly creatinine clearances were 71.5 +/- 8.6 versus 35.1 +/- 1.3 L (P less than 0.001), and EN were 7.4 +/- 0.8 versus 3.6 +/- 0.2 L/g of creatinine/day (P less than 0.005). Creatinine kinetics (weekly clearance and EN) but not urea kinetics could differentiate group I (N = 4) from groups G or P. Both urea and creatinine kinetics predict clinical outcome in CAPD.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

尿素动力学(Kt/V,其中K为尿素清除率,t为治疗时间,V为尿素分布容积)用于评估持续性非卧床腹膜透析(CAPD)充分性及临床结局的有效性尚未经过前瞻性验证,横断面临床研究也尚无定论。建议每周肌酐清除率至少为40至50L,但该剂量的充分性未经证实。我们引入了一种更简单的肌酐动力学方法,即根据标准化4小时留腹交换获得的数据计算出的效能指数(EN)。为确定预测CAPD充分性的最有效模型,对18例稳定的CAPD患者进行了前瞻性随访至少12个月,测量了其残余肾功能、每周尿素Kt/V、根据体表面积标准化的每周肌酐清除率以及EN(每天每克肌酐的升数)。根据尿毒症症状、死亡率、住院天数、生化指标以及转血液透析的需求,将患者分为三组:良好(G)、中等(I)和差(P)。比较G组(N = 6)和P组(N = 8)时,每周Kt/V分别为2.3±0.2与1.5±0.1(P<0.005),每周肌酐清除率分别为71.5±8.6与35.1±1.3L(P<0.001),EN分别为7.4±0.8与3.6±0.2L/g肌酐/天(P<0.005)。肌酐动力学(每周清除率和EN)而非尿素动力学能够区分I组(N = 4)与G组或P组。尿素和肌酐动力学均可预测CAPD的临床结局。(摘要截选至250词)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验